Michael Wasserman
Managing Director @ H.I.G. BioHealth Partners
Toronto, Canada
Michael Wasserman is a Series B investor at H.I.G. BioHealth Partners in Toronto focused on Health Care and Biotechnology. Michael focuses on investments in therapeutics and medical devices and currently serves as a director or board observer for H.I.G. portfolio companies: HyperBranch Medical Technology, Clarus Therapeutics, Tranzyme Pharma, and CardioFocus.Prior to joining H.I.G., Michael was a Principal at Innovations Foundation, focused on the creation,financing and development of high technology companies in the life sciences, information technology and engineering sectors. At Innovations Foundation, Michael was instrumental in building multiple high growth companies derived from academic or federally sponsored research programs. Michael has also held prominent operating roles in several entrepreneurial and venture-backed life sciences efforts. Michael was a founder and Vice President, Business Development at CELLutions Biosystems (acquired by Cedarlane Laboratories), where he broadly managed business operations and was directly responsible for the successful negotiation of partnership, co-development and licensing agreements with industry leading pharmaceutical and biotechnology organizations. Michael also has extensive clinical research experience. As Director of Research at Advanced Therapeutics, Michael was involved in a series of seminal clinical studies involving biological approaches to treat rheumatoid arthritis and other autoimmune and inflammatory disorders. Earlier in his career, Michael worked directly for, or as a consultant to, several early stage life sciences businesses, and in the corporate finance, pharmaceutical and clinical research industries.Michael received his B.Sc. from McGill University and his Ph.D. in Pharmacology from the University of Toronto.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 64%
Last updated:
For AI agents: llms.txt
Industries Michael Wasserman invests in
Stages Michael Wasserman invests in
Countries Michael Wasserman invests in
Investment Focus
Industry
- Health Care 5 (45%)
- Biotechnology 5 (45%)
- Medical Device 5 (45%)
- Therapeutics 2 (18%)
- Pharmaceutical 2 (18%)
Stage
- Series B 3 (27%)
- Series C 3 (27%)
- Series A 1 (9%)
- Series D 1 (9%)
- Debt Financing 1 (9%)
Country
- United States 4 (36%)
- Ireland 1 (9%)
- United Kingdom 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Nuclera
|
Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery. | $12M / Series C / Jan 13, 2026 | |
FIRE1
|
FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices. | $120M / Series B / Jan 07, 2025 | |
|
Nuclera
|
Nuclera offers a protein prototyping system to accelerate drug discovery by making proteins readily available to researchers. Nuclera's eProtein DiscoveryTM system allows scientists to rapidly produce and test proteins for drug discovery. | $75M / Series C / Oct 15, 2024 | |
Moximed
|
Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $61M / Series D / Aug 13, 2024 | |
Agora Brands
|
Agora is an ecommerce aggregation business that acquires existing sub-scale brands that sell directly to consumers through Shopify stores and other D2C ecommerce platforms. | $83.5M / Private Equity / May 10, 2022 | |
Zerigo Health
|
Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions.Clarify Medicalindicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction. | $43M / Series B / Oct 21, 2021 | |
|
Zerigo Health
|
Clarify Medical is innovating a well-established treatment, UVB therapy, to become easier, more convenient, more empowering, and more connected for psoriasis, eczema and vitiligo patients. The company also focused on developing innovative technology, products, and services that improve care for people with chronic skin conditions.Clarify Medicalindicated for the localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of UVB light therapy, helping to ensure that patients receive the proper doses recommended by the American Academy of Dermatology and Vitiligo Working Group. The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress, and satisfaction. | $18M / Series A / Oct 23, 2019 | |
NeuWave Medical
|
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highestquality devices that are the products of choice for leading physicians and medical centers around the world.The company was founded in 2004 and is headquartered in Madison, Wisconsin. | $25.3M / Series C / May 22, 2015 | |
CardioFocus
|
CardioFocus is a biotechnology company that focuses on the advancement of ablation treatments for cardiac disorders. The company specializes in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation that focuses on developing, manufacturing, andinvestigating disposable fiber optic catheters for the visualization of the cardiac anatomy and the treatment of cardiac arrhythmias.CardioFocus was founded in 1990 and is headquartered in Marlborough, Massachusetts. | Debt Financing / May 09, 2014 | |
|
NeuWave Medical
|
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highestquality devices that are the products of choice for leading physicians and medical centers around the world.The company was founded in 2004 and is headquartered in Madison, Wisconsin. | $14M / Series B / Sep 05, 2012 | |
| See all 11 investments → | |||
Co-Investors
About H.I.G. BioHealth Partners
H.I.G. BioVentures invests in a broad range of life science companies across multiple sectors and stages of development. Their seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. They invest in companies developing novelproducts for significant unmet medical needs.
H.I.G. BioHealth Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bruce Robertson
Managing Director
|
|||
Jorge Ramirez
Vice Presidents
|
|||
Aaron Davidson
Managing Director
|
|||
|
Michael Wasserman
Managing Director
|
|||
Sami Mnaymneh
Co-Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michael Wasserman invest in?
Michael Wasserman invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Michael Wasserman last invest?
The most recent investment recorded for Michael Wasserman closed in Jan 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
